Table 2.
Variablesa | N | Ciprofloxacinc | pd | |
---|---|---|---|---|
Susceptible | Decreased susceptibility | |||
Age (years) | ||||
0–14 | 162 (40.3%) | |||
5–59 | 110 (27.4%) | |||
≥ 60 | 130 (32.3%) | |||
Sex | ||||
Male | 256 (63.7%) | 250 (63.6%) | 6 (66.7%) | 1.000 |
Female | 146 (36.3%) | 143 (36.3%) | 3 (33.3%) | 1.000 |
Prevalent seasons (months) | ||||
3–5 | 138 (34.3%) | |||
6–8 | 67 (16.7%) | |||
9–11 | 54 (13.4%) | |||
12–2 | 143 (35.6%) | |||
Underlying diseases | ||||
Chronic obstructive pulmonary disease | 60 (14.9%) | 58 (14.7%) | 2 (22.2%) | 0.626 |
Hypertension | 70 (17.4%) | 68 (17.3%) | 2 (22.2%) | 1.000 |
Diabetes | 28 (7.0%) | 27 (6.9%) | 1 (11.1%) | 1.000 |
Chronic kidney disease | 33 (8.2%) | 33 (8.4%) | 0 (0%) | 1.000b |
Cancers | 46 (11.4%) | 45 (11.5%) | 1 (11.1%) | 1.000 |
Interstitial lung Disease | 14 (3.5%) | 1 3(3.3%) | 1 (11.1%) | 0.732 |
Bronchiectasia | 27 (6.7%) | |||
Causes | ||||
Catch cold or be tired | 30 (7.5%) | 27 (6.9%) | 3 (33.3%) | 0.019 |
Invasive procedure | 27 (6.7%) | 24 (6.1%) | 3 (33.3%) | 0.011 |
History of smoking | 40 (9.9%) | 39 (9.9%) | 1 (11.1%) | 1.000 |
Channel of infection | ||||
Community-acquired | 372 (92.5%) | |||
Hospital-acquired | 30 (7.5%) | |||
Hospitalization during previous 3 months | 133 (33.1%) | 128 (32.6%) | 5 (55.6%) | 0.147 |
Fluoroquinolones use during previous 3 months | 5 (1.2%) | 7 (1.8%) | 2 (22.2%) | 0.003 |
Antimicrobial use during previous 3 months | ||||
Cephalosporins | 144 (36.6%) | 4 (44.4%) | 0.896 | |
Azithromycin | 70 (17.8%) | 0 (0%) | 0.370b | |
Piperacillin | 13 (3.3%) | 1 (11.1%) | 0.732 | |
Multidrug resistant strains | 55 (14.0%) | 8 (88.9%) | 0.000 |
a Data are presented as mean ± SD or number of patients (%)
bFisher’s exact test
cNumbers of susceptible and decreased susceptibility are 393 and 9, respectively
dStatistically significant data are in italics